Pawełczyk Konrad, Marciniak Marek, Błasiak Piotr
Department of General Thoracic Surgery, Wroclaw Thoracic Surgery Centre, Wroclaw Medical University, Wroclaw, Poland.
J Cardiothorac Surg. 2016 Apr 14;11(1):68. doi: 10.1186/s13019-016-0456-5.
The aim of the study was to evaluate the prognostic power of new classifications of N descriptor created basing on the number (NLN) and the ratio of metastatic lymph nodes (RLN) in NSCLC compared to the current classification (CLN).
The data of 529 patients with NSCLC operated with the intention of radical resection, were analyzed. The new categories of N descriptor were created as follows: 1) NLN - median number of metastatic nodes was 3, thus in NLN0 the number of metastatic nodes =0, in NLN1 1-2, in NLN2 ≥ 3, 2) RLN - median ratio (number of metastatic lymph nodes to all nodes removed) was 12.4 %, thus in RLN0 the ratio was 0, in RLN1 < 13 %, in RLN2 > 13 %. The prognostic value of each classification was calculated on the basis of hazard ratios defined in multivariate Cox proportional hazard model.
The new classifications of N descriptor turned out to be an independent strong prognostic factor (p <0.001) with a 5-year survival rate NLN0-62 %, NLN1-39 %, NLN2-26 % and RLN0-62 %, RLN1-37 % and RLN2-26 %. For 5-year survival rates in CLN0-62 %, CLN1-42 %, CLN2-24 % (p < 0.001), a higher prognostic value of new classifications was not demonstrated, the hazard ratio amounted to 2.22, 2.08, 2.49 for NLN2, RLN2 and CLN2 respectively.
Despite the significantly high prognostic power, the new classifications cannot be considered superior over CLN. There are some deficiencies in the current classification, therefore further studies on its improvement are needed.
本研究旨在评估基于非小细胞肺癌(NSCLC)转移淋巴结数量(NLN)和转移淋巴结比例(RLN)创建的N描述符新分类与当前分类(CLN)相比的预后预测能力。
分析了529例接受根治性切除手术的NSCLC患者的数据。N描述符的新类别创建如下:1)NLN - 转移淋巴结的中位数为3,因此在NLN0中转移淋巴结数量 = 0,在NLN1中为1 - 2,在NLN2中≥3;2)RLN - 中位数比例(转移淋巴结数量与切除的所有淋巴结数量之比)为12.4%,因此在RLN0中该比例为0,在RLN1中<13%,在RLN2中>13%。基于多变量Cox比例风险模型中定义的风险比计算每种分类的预后价值。
N描述符的新分类被证明是一个独立的强预后因素(p <0.001),5年生存率分别为NLN0 - 62%,NLN1 - 39%,NLN2 - 26%以及RLN0 - 62%,RLN1 - 37%,RLN2 - 26%。CLN0 - 62%,CLN1 - 42%,CLN2 - 24%(p <0.001)的5年生存率方面,未显示新分类具有更高的预后价值,NLN2、RLN2和CLN2的风险比分别为2.22、2.08、2.49。
尽管新分类具有显著高的预后预测能力,但不能认为其优于CLN。当前分类存在一些不足,因此需要进一步研究对其进行改进。